Claims
- 1. In a method of treating a cystic fibrosis patient with a bactericidal/permeability-increasing (BPI) protein product, the improvement comprising administering an N-terminal BPI protein product to a subject having non-N-terminal-BPI-reactive antibodies.
- 2. The method of claim 1 wherein the N-terminal BPI protein product is being administered to the cystic fibrosis patient to ameliorate adverse effects associated with endotoxin in circulation.
- 3. The method of claim 1 wherein the N-terminal BPI protein product is being administered to the cystic fibrosis patient to ameliorate adverse effects associated with meningococcemia.
- 4. The method of claim 1 wherein the N-terminal BPI protein product is being administered to the cystic fibrosis patient to ameliorate adverse effects associated with hemorrhagic trauma.
- 5. The method of claim 1 wherein the N-terminal BPI protein product is being administered to the cystic fibrosis patient to ameliorate adverse effects associated with burn injury.
- 6. The method of claim 1 wherein the cystic fibrosis patient being treated is suffering from a gram-negative bacterial infection.
- 7. The method of claim 1 wherein the cystic fibrosis patient being treated is suffering from a gram-positive bacterial or mycoplasmal infection.
- 8. The method of claim 1 wherein the cystic fibrosis patient being treated is suffering from a fungal infection.
- 9. The method of claim 1 wherein the cystic fibrosis patient being treated is suffering from a protozoan infection.
- 10. The method of claim 1 wherein the cystic fibrosis patient being treated is suffering from a chlamydial infection.
- 11. The method of claim 1 wherein the cystic fibrosis patient being treated is suffering from a mycobacterial infection.
- 12. The method of claim 1 wherein the cystic fibrosis patient being treated is suffering from a chronic inflammatory disease.
- 13. The method of claim 1 wherein the N-terminal BPI protein product is being administered to cystic fibrosis patient to inhibit angiogenesis.
- 14. The method of claim 1 wherein the N-terminal BPI protein product is being administered to the cystic fibrosis patient to promote fibrinolysis.
- 15. The method of claim 1 wherein the N-terminal BPI protein product is an amino-terminal fragment of BPI protein having a molecular weight of about 20 kD to 25 kD.
- 16. The method of claim 1 wherein the N-terminal BPI protein product is rBPI23 or a dimeric form thereof.
- 17. The method of claim 1 wherein the N-terminal BPI protein product is rBPI21.
- 18. A composition for aerosol delivery comprising a BPI protein product and a poloxamer surfactant at a concentration of 0.3% or more.
- 19. The composition of claim 18 further comprising 0.002% or more polysorbate 80 by weight.
- 20. The composition of claim 18 wherein the poloxamer surfactant is poloxamer 188 at a concentration of 0.3% by weight.
- 21. The composition of claim 18 wherein the poloxamer surfactant is poloxamer 333 at a concentration of 0.4% by weight.
- 22. An improved method of administering a BPI protein product to a patient suffering from cystic fibrosis, comprising administering the composition of claim 18 to said patient via aerosol delivery.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. Ser. No. 08/742,986 filed Nov. 1, 1996, incorporated herein by reference.
Continuations (1)
|
Number |
Date |
Country |
Parent |
08962217 |
Oct 1997 |
US |
Child |
09480234 |
Jan 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08742986 |
Nov 1996 |
US |
Child |
09480234 |
Jan 2000 |
US |